Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion

Abstract Background Renal cell carcinomas (RCC) harboring a TFE3 gene fusion (TfRCC) represent an aggressive subset of kidney tumors. Key signaling pathways of TfRCC are unknown and preclinical in vivo data are lacking. We investigated Akt/mTOR pathway activation and the preclinical efficacy of dual...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Eric C. Kauffman, Martin Lang, Soroush Rais-Bahrami, Gopal N. Gupta, Darmood Wei, Youfeng Yang, Carole Sourbier, Ramaprasad Srinivasan
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2019-09-01
Serie:	BMC Cancer
Soggetti:	TFE3 MITF Translocation renal cell carcinoma Fusion gene mTOR inhibitor AZD8055
Accesso online:	http://link.springer.com/article/10.1186/s12885-019-6096-0
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!